Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 1999

View Archived Issues

SIV isolates from chimpanzees closely related to HIV-1

Additional adverse reactions added to Flovent's package insert

Ligand purchases Marathon Biopharmaceuticals' assets

Interneuron: Q1 1999 highlights

Medco: Q4 and FY98 highlights

Aronex initiates phase I/II trial of Atragen + interferon alfa in renal cell carcinoma

Protease inhibitors awarded 1998 Prix Galien

Focal angiogenic gene therapy as a novel treatment for myocardial ischemia

ProScript initiates second phase I trial for PS-341

New formulation of Zofran receives marketing clearance in the U.S.

Promising results obtained with activated immune cell therapies in development at Proneuron

Human Genome Sciences initiates phase II clinical trials of new wound-healing agent

New patent expands OSI's gene transcription patent estate

Novel NOS inhibitors prepared at Astra, claimed for use in inflammatory disorders

SmithKline Beecham claims new series of inhibitors of cytokine production

Na+/H+ antiport inhibitors in development at Synthelabo

Cellegy initiates clinical trial with transdermal testosterone gel

U.S. university researchers claim anti-HIV 2',5'-phosphorothioate/phosphodiester oligoadenylates

U. of Arizona prepares novel cyanoaziridine-based antitumor agents

Review supports hCG as a target for cancer immunotherapy

New synthetic hepatoprotectant under study in India

Results published from preclinical study comparing CVT-510 and diltiazem

Available for licensing from NIH: BOG gene and protein product for Rx, Dx use

Angiotensin II blocker/diuretic combination product added to Spanish pharmacopeia

Update on AstraZeneca merger proceedings

Roche recovers marketing rights for beta-blocker in most markets

Mechanism of action of T-614 in RA examined in vitro

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...